Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Wound Healing Process in Diabetic Neuropathy and Diabetic Neuroischemia (Geko)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02378909
Recruitment Status : Unknown
Verified March 2015 by Ahmad Najib bin Hasan, University of Manchester.
Recruitment status was:  Not yet recruiting
First Posted : March 4, 2015
Last Update Posted : March 26, 2015
Sponsor:
Collaborators:
Manchester University NHS Foundation Trust
Firstkind Ltd
Information provided by (Responsible Party):
Ahmad Najib bin Hasan, University of Manchester

Brief Summary:
Diabetes mellitus is one of the leading causes of illness worldwide. Diabetes can affect nerves, skin and blood vessels. Diabetics with problems in their nerves can lose the sense of touch in their feet (called neuropathy) and so may unknowingly cause damage to the skin resulting in skin loss or an 'ulcer'. Diabetics also have difficulty healing any damaged tissues especially if the patients have diseased blood vessels causing a lack of blood to areas of the body including the feet (called ischaemia).

Condition or disease Intervention/treatment Phase
Diabetes Device: Electrical stimulation device. Phase 1

Detailed Description:

Diabetes mellitus is one of the leading causes of illness worldwide. Diabetes can affect nerves, skin and blood vessels. Diabetics with problems in the patients nerves can lose the sense of touch in the patient's feet (called neuropathy) and so may unknowingly cause damage to the skin resulting in skin loss or an 'ulcer'. Diabetics also have difficulty healing any damaged tissues especially if the patient have diseased blood vessels causing a lack of blood to areas of the body including the feet (called ischaemia). Therefore diabetics have a greater chance of having an ulcer and a higher chance that it does not heal up. The loss of a protective skin barrier means that bacteria can enter the foot causing infections which can spread to bone and beyond. Ultimately this can result in gangrene, amputation or even death.

Stem or progenitor cells help repair and replace damage in the body. Blood vessels are key to this repair. Recent research has suggested that special progenitor cells found in the blood may be responsible. They are called Endothelial Progenitor Cells (EPCs) and seem to be in fewer numbers and are less effective at repair in diabetics.

Current treatments for diabetic wounds are not always successful and so the investigators need more research to look at new treatments. One possibility is to use electrical stimulation of nerves in the leg. Research studies have shown this may improve blood circulation and healing of wounds. This research will assess EPCs to see if they are linked to ulcer healing in diabetic patients with neuropathy only or with ischaemia as well. Furthermore the investigators wish to investigate whether electrical stimulation can affect progenitor cells and wound healing in these patients. The longterm goal of this research is to help diabetic patients improve their quality of life by reducing wound related complications

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Diabetic Wound Healing and Its Relationship to Vascular Circulation.
Study Start Date : April 2015
Estimated Primary Completion Date : April 2016
Estimated Study Completion Date : April 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Group 1
Diabetic Neuropathy with electrical stimulation device and standard of care.
Device: Electrical stimulation device.
In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
Other Name: GekoTM Device

No Intervention: Group 2
Diabetic neuropathy with standard of care.
Active Comparator: Group 3
Diabetic neuroischemia with electrical stimulation device and standard of care.
Device: Electrical stimulation device.
In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
Other Name: GekoTM Device

No Intervention: Group 4
Diabetic neuroischemia with standard of care.



Primary Outcome Measures :
  1. Improvement in ulcer size at monthly intervals up to 12 months follow up. [ Time Frame: 12 months ]
    The wound will be measured after the electrical stimulation produced by Geko device is applied.


Secondary Outcome Measures :
  1. Proportion of wounds healed at monthly intervals up to 12 months followup [ Time Frame: 12 months ]
    Percentage of wounds healed after the electrical stimulation produced by Geko device is applied.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Consenting patients with Type 1 or 2 diabetes.
  • Male or female, aged 18-85 years.
  • Presence of significant neuropathic ulcers.
  • Presence of significant neuroischaemic ulcers.
  • Patients who are able and willing to follow the protocol requirements.

Exclusion Criteria:

  • Unreliable, unwilling or unable to comprehend informed consent.
  • Patients with recently diagnosed or with suspected deep vein thrombosis (DVT).
  • Patients without neuroischaemic/ neuropathic ulcers
  • Patients with cardiac demand pacemakers.
  • Patients who are pregnant.
Layout table for additonal information
Responsible Party: Ahmad Najib bin Hasan, Mr, University of Manchester
ClinicalTrials.gov Identifier: NCT02378909    
Other Study ID Numbers: UManchester
First Posted: March 4, 2015    Key Record Dates
Last Update Posted: March 26, 2015
Last Verified: March 2015